[{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG302","moa":"Synapses","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2a\/5-HT2c\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine\/Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Alvogen"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cap Alter Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cap Alter Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cap Alter Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ DCH Auriga"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distribution Solutions"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distriphil"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ ICI Pakistan Limited"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zuellig Pharma"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioXcel Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Braeburn","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Braeburn","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Braeburn"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Altruix"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Chlordiazepoxide","moa":"||Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"Hims","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hims","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hims \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hims \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Zuellig Pharma"},{"orgOrder":0,"company":"Fabre-Kramer Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fabre-Kramer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Fabre-Kramer Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fabre-Kramer Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Sage Chemical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Sage Chemical","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Sage Chemical"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Harm Reduction Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1\/OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Alar Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Johnson & Johnson"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ Janssen Biotech"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ketamine Wellness Center","sponsor":"Delic Corp","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ketamine Wellness Center","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ketamine Wellness Center \/ Delic Corp","highestDevelopmentStatusID":"15","companyTruncated":"Ketamine Wellness Center \/ Delic Corp"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Haloperidol Decanoate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Neos Therapeutics \/ Aytu BioPharma"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Lupin Pharma Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aytu BioPharma \/ Lupin Pharma Canada","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Lupin Pharma Canada"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Medison Pharma"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Orexo \/ Accord healthcare"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Brand Institute \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"Alora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka America Pharmaceutical, Inc.","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka America Pharmaceutical, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Holdings"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Holdings \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Holdings \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Auxilium Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hims & Hers Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Hims & Hers Health","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Hims & Hers Health"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Neurotrope","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Neurotrope"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adlon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adlon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adlon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Societal CDMO \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"InfectoPharm Drugs and Consilium \/ Societal CDMO","highestDevelopmentStatusID":"15","companyTruncated":"InfectoPharm Drugs and Consilium \/ Societal CDMO"},{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sprout Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sprout Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sprout Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Angelini Pharma \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Angelini Pharma \/ Sunovion Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Perigon Pharmacy 360","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Perigon Pharmacy 360","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Perigon Pharmacy 360"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRL-4","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Starton Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Starton Therapeutics \/ Love Pharma"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ingenu","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ingenu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ingenu \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Ingenu \/ Psyence"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Cantheon Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Cantheon Capital","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Cantheon Capital"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Newcourt Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Newcourt Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Newcourt Acquisition Corp"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence Biomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence Biomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ UCLA"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"2","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numinus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Numinus \/ Inapplicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numinus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Numinus \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA A-alpha-4\/beta-2\/delta receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"DCR-A1203","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"ABMRF","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ ABMRF","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ ABMRF"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"PsyLabs","sponsor":"Psyence Biomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyLabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PsyLabs \/ Psyence Biomed","highestDevelopmentStatusID":"6","companyTruncated":"PsyLabs \/ Psyence Biomed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"5 Horizons Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ 5 Horizons Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ 5 Horizons Capital"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aragen Life Sciences \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Clearmind Medicine"},{"orgOrder":0,"company":"SABI Mind","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SABI Mind","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SABI Mind \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SABI Mind \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tempero Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Tempero Bio \/ 8VC","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ 8VC"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ IMP Clinical Supply Services"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Origin Therapeutics","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Origin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Origin Therapeutics \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Origin Therapeutics \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov Therapeutics \/ ECSOR"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Adenomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Adenomed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Adenomed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Boudicca Dx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Boudicca Dx","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Boudicca Dx"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Maxim Group LLC"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Awakn Life Sciences Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Cybin","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Cybin"},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Camino Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camino Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Camino Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Journey Colab","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Journey Colab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Colab \/ MBX Capital","highestDevelopmentStatusID":"4","companyTruncated":"Journey Colab \/ MBX Capital"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adamis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Psilera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PSIL-006","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psilera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Inapplicable"},{"orgOrder":0,"company":"Awakn Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Awakn Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Awakn Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Awakn Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"B.More","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B.More \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ Inapplicable"},{"orgOrder":0,"company":"B.More","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B.More \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPJ-001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Xpira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Xpira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xpira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xpira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Kings College London","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Kings College London","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Kings College London"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BRII-297","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Endosane Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"PreveCeutical Medical \/ Endosane Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Endosane Pharmaceuticals"},{"orgOrder":0,"company":"GABA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GABA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"GABA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GABA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glyph Allopregnanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seaport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Incannex Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Incannex Healthcare"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Baergic Bio","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"BAER-101","moa":"GABAA-alpha-2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Baergic Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baergic Bio \/ Avenue Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Baergic Bio \/ Avenue Therapeutics"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Grossman School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Grossman School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Filament Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Filament Health","highestDevelopmentStatusID":"5","companyTruncated":"Psyence \/ Filament Health"},{"orgOrder":0,"company":"Filament Health","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Filament Health \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ Psyence"},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VQW-765","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Loxapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Controlled Substance","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Pharmanovia"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Mind Medicine"},{"orgOrder":0,"company":"Cannex Scientific","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cannex Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cannex Scientific \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Cannex Scientific \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Vectura Fertin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurora Cannabis \/ Vectura Fertin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aurora Cannabis \/ Vectura Fertin Pharma"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Synendos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cannabidiol","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Marijuana Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tetrahydrocannabinol Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tetrahydrocannabinol Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ MZ Group","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ MZ Group"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"4-Ethylphenol Sulfate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldfinch Bio, Inc \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Goldfinch Bio, Inc \/ Karuna Therapeutics"},{"orgOrder":0,"company":"Sensorium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"SENS-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sensorium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sensorium Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Avance Clinical"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntelGenx \/ Cybin","highestDevelopmentStatusID":"1","companyTruncated":"IntelGenx \/ Cybin"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic-alpha-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Monash University","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Monash University"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Series B Financing","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Engrail Therapeutics \/ F-Prime Capital","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ F-Prime Capital"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlordiazepoxide","moa":"||Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Exhale Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exhale Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Monash University","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Monash University \/ Incannex Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Monash University \/ Incannex Healthcare"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"BDD Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ BDD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ BDD Pharma"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Mylan Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Lorazepam","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Mylan Group","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Mylan Group"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Almirall \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Neuraxpharm"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Leerink Partners"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Mitacs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Mitacs"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVM201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Basel \/ Mind Medicine"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"GRI Bio \/ Aardvark Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ Aardvark Therapeutics"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Magdalena Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Magdalena Biosciences \/ Jaguar Health","highestDevelopmentStatusID":"4","companyTruncated":"Magdalena Biosciences \/ Jaguar Health"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiefenbacher Group \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Tiefenbacher Group \/ OnDosis"},{"orgOrder":0,"company":"3Z","sponsor":"biotx.ai","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ICELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"3Z","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"3Z \/ biotx.ai","highestDevelopmentStatusID":"2","companyTruncated":"3Z \/ biotx.ai"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ The Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ The Lind Partners"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Commave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Commave Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Commave Therapeutics"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Corium","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Hercules Capital"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IQVIA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Centanafadine","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Aegis Capital"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Indegene","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indegene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Indegene \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Indegene \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centanafadine","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Cediprof","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cediprof"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dasotraline","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Controlled Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Controlled Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Medomie","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Medomie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Medomie \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Medomie \/ Aytu BioPharma"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Magnesium L-Threonate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Neurocentria","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocentria \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurocentria \/ Inapplicable"},{"orgOrder":0,"company":"3Z","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"3Z","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3Z \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"3Z \/ Inapplicable"},{"orgOrder":0,"company":"Liechti Laboratory","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Liechti Laboratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liechti Laboratory \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Liechti Laboratory \/ Mind Medicine"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Maastricht University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Maastricht University","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Maastricht University"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphetamine","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"King\u2019s College London","sponsor":"Compass Pathways","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"King\u2019s College London","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"King\u2019s College London \/ Compass Pathways","highestDevelopmentStatusID":"4","companyTruncated":"King\u2019s College London \/ Compass Pathways"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Shaare Zedek Scientific Ltd.\u00a0","sponsor":"Greater Cannabis Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shaare Zedek Scientific Ltd.\u00a0","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company","highestDevelopmentStatusID":"1","companyTruncated":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"National Institutes of Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rumi Scientific \/ National Institutes of Mental Health","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ National Institutes of Mental Health"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisinicline Analog","moa":"Nicotinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"NFL Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"NFL-301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athena Pharmaceutiques \/ NFL Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Athena Pharmaceutiques \/ NFL Biosciences"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Praxis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ University of Florida"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Westar Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Westar Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Westar Capital Limited"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACT-539313","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Anson Funds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Anson Funds","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Anson Funds"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HOPE Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Merger","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HOPE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HOPE Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"HOPE Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Government of Canada"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Alvogen","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Alvogen"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"NeuroRX Pharma","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NeuroRX Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroRX Pharma \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"NeuroRX Pharma \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Streeterville Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Streeterville Capital","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Streeterville Capital"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Laboratoires Delbert","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Lithium Carbonate","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Laboratoires Delbert","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Laboratoires Delbert"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Campbell Neurosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Campbell Neurosciences","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Campbell Neurosciences"},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"The University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of British Columbia \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"The University of British Columbia \/ Inapplicable"},{"orgOrder":0,"company":"Neurotheryx","sponsor":"Cyclica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neurotheryx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotheryx \/ Cyclica","highestDevelopmentStatusID":"1","companyTruncated":"Neurotheryx \/ Cyclica"},{"orgOrder":0,"company":"University of Oxford","sponsor":"BD2","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ BD2","highestDevelopmentStatusID":"2","companyTruncated":"University of Oxford \/ BD2"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"4M Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Nice & Green"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Bar-Ilan University"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Agreement","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Metyrapone","moa":"||CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embera NeuroTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"BIRAD","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BIRAD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BIRAD \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BIRAD \/ Clearmind Medicine"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Phoenix Pharmalabs \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPX-101","moa":"Alpha-5-GABAA-R","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monument Therapeutics","sponsor":"Forster Foundation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"MT1988","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Monument Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monument Therapeutics \/ Forster Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Monument Therapeutics \/ Forster Foundation"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"FAV LS Fund I","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ FAV LS Fund I","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ FAV LS Fund I"},{"orgOrder":0,"company":"Reset Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Reset Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reset Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Reset Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eleusis","sponsor":"Silver Spike Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eleusis \/ Silver Spike Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Eleusis \/ Silver Spike Acquisition Corp"},{"orgOrder":0,"company":"Eleusis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eleusis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eleusis \/ Inapplicable"},{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"6","companyTruncated":"Eleusis \/ Beckley Psytech"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Undisclosed \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"LTS - Lohmann Therapie Systeme \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohmann Therapie Systeme \/ PharmaTher"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Magdalena Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jaguar Health \/ Magdalena Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Health \/ Magdalena Biosciences"},{"orgOrder":0,"company":"Sansero Life Sciences","sponsor":"University of Toronto","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sansero Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sansero Life Sciences \/ University of Toronto","highestDevelopmentStatusID":"4","companyTruncated":"Sansero Life Sciences \/ University of Toronto"},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"CB Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"1","companyTruncated":"CB Therapeutics \/ Cleveland Clinic"},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"One Small Planet","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Magdalena Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Magdalena Biosciences \/ One Small Planet","highestDevelopmentStatusID":"1","companyTruncated":"Magdalena Biosciences \/ One Small Planet"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evotec","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Pasithea Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Pasithea Therapeutics"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Brain and Cognition Discovery Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Braxia Scientific \/ Brain and Cognition Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Brain and Cognition Discovery Foundation"},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"Champignon","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dalriada Drug Discovery \/ Champignon","highestDevelopmentStatusID":"4","companyTruncated":"Dalriada Drug Discovery \/ Champignon"},{"orgOrder":0,"company":"NeuroPharma","sponsor":"Mydecine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NeuroPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroPharma \/ Mydecine","highestDevelopmentStatusID":"1","companyTruncated":"NeuroPharma \/ Mydecine"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Mydecine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leiden University Medical Center \/ Mydecine","highestDevelopmentStatusID":"4","companyTruncated":"Leiden University Medical Center \/ Mydecine"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Rugen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"GM-1020","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilgamesh Pharmaceuticals \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Gilgamesh Pharmaceuticals \/ Prime Movers Lab"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yiling Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Series B Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Nuformix","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"4-Chlorokynurenine","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuformix \/ VistaGen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imperial College London \/ Compass Pathways","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Compass Pathways"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"NV-5138","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HMNC Brain Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Inapplicable"},{"orgOrder":0,"company":"Psirenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psirenity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Psirenity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Psirenity \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"5-HT transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ansofaxine HCl","moa":"5-HT\/norepinephrine\/dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"INmune Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RP1208","moa":"Triple reuptake","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Advanced Biofuels","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Norbaeocystin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PsyBio Therapeutics \/ Advanced Biofuels","highestDevelopmentStatusID":"6","companyTruncated":"PsyBio Therapeutics \/ Advanced Biofuels"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MindBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MindBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MindBio Therapeutics"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MycoMedica Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MycoMedica Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MycoMedica Life Sciences"},{"orgOrder":0,"company":"Psilera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psilera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"Field Trip Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FT-104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Field Trip Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip Health \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NemaLife","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Psychoplastogen","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NemaLife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NemaLife \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"NemaLife \/ University of California"},{"orgOrder":0,"company":"Delos Psyche Research Group","sponsor":"New Wave Holdings Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Funding","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delos Psyche Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delos Psyche Research Group \/ New Wave Holdings Corp","highestDevelopmentStatusID":"1","companyTruncated":"Delos Psyche Research Group \/ New Wave Holdings Corp"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Seleni Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ Seleni Institute","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Seleni Institute"},{"orgOrder":0,"company":"Cadent Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"MIJ821","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cadent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cadent Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Cadent Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Carleton University"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Bloom Psychedelic Therapy and Research Centre","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Vella Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vella Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vella Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vella Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"University of Barcelona","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"Akome Biotech \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biotech \/ University of Barcelona"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Healis Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Serotype A Botulinum Toxin","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Healis Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Healis Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apimostinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gate Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Apimostinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gate Neurosciences \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVX-301","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kalypso Wellness Centers","sponsor":"Eleusis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ELE-Psilo+","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Kalypso Wellness Centers","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kalypso Wellness Centers \/ Eleusis","highestDevelopmentStatusID":"6","companyTruncated":"Kalypso Wellness Centers \/ Eleusis"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Acadia Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Vyera Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Vyera Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Cybin","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Cybin"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-203","moa":"H3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BTRX-140","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BlackThorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1070770","moa":"NMDA subunit-2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaseed","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pharmaseed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pharmaseed \/ Mira Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaseed \/ Mira Pharmaceuticals"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Abu Dhabi Growth Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Abu Dhabi Growth Fund","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Abu Dhabi Growth Fund"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"BlackThorn Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ BlackThorn Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ BlackThorn Therapeutics"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-155","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-155","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilgamesh Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilgamesh Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Miralogx","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Miralogx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Miralogx \/ Mira Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Miralogx \/ Mira Pharmaceuticals"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Canaan Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Canaan Partners"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Xinnovation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Xinnovation Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Xinnovation Therapeutics"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UC San Diego","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UC San Diego \/ BetterLife Pharma","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ BetterLife Pharma"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nortriptyline","moa":"NET","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Negev Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Negev Capital","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Negev Capital"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Alliance Global Partners"},{"orgOrder":0,"company":"Cybin","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Bloom Burton Securities","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Deep Track Capital"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Firefly Neuroscience","sponsor":"Arrivo BioVentures","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Firefly Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Firefly Neuroscience \/ Arrivo BioVentures","highestDevelopmentStatusID":"8","companyTruncated":"Firefly Neuroscience \/ Arrivo BioVentures"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Carleton University"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Nucro-Technics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Nucro-Technics","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Nucro-Technics"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"MYND Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of British Columbia \/ MYND Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ MYND Life Sciences"},{"orgOrder":0,"company":"Sunstone Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunstone Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sunstone Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sunstone Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"||GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Orlando Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Orlando Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Orlando Health Ventures"},{"orgOrder":0,"company":"Fluence","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Fluence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fluence \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Fluence \/ Cybin"},{"orgOrder":0,"company":"Facet Life Sciences","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Facet Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Facet Life Sciences \/ Cybin","highestDevelopmentStatusID":"10","companyTruncated":"Facet Life Sciences \/ Cybin"},{"orgOrder":0,"company":"Usona Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Usona Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Institute \/ Inapplicable"},{"orgOrder":0,"company":"Usona Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Usona Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Institute \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"MYND Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MYND Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"MYND Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MYND Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"5-HT transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Cowen"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Eventide Asset Management","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Eventide Asset Management"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ BofA Securities"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"HMNC Brain Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ HMNC Brain Health","highestDevelopmentStatusID":"6","companyTruncated":"Spruce Biosciences \/ HMNC Brain Health"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Cerebral Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Cerebral Therapeutics"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Lightswitch Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Lightswitch Capital"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Osavampator","moa":"AMPA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pipamperone","moa":"5-HT2A\/D4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANeuroTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Inapplicable"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pipamperone","moa":"||5-HT2A\/D4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANeuroTech \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Johnson & Johnson"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Selective-5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAA1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gate Neurosciences \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Beacon Biosignals"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Seltorexant","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Royalty Pharma"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Arbormentis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Arbormentis","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Arbormentis"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Intellipharmaceutics Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Desvenlafaxine Succinate","moa":"5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Taro Pharmaceutical Industries \/ Intellipharmaceutics Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Intellipharmaceutics Corporation"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Chinalink Asia Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pramipexole DiHCl","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Chase Therapeutics \/ Chinalink Asia Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Chase Therapeutics \/ Chinalink Asia Holdings"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||5-HT\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The Queen's University of Belfast","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Infusion","sponsorNew":"PharmaTher \/ The Queen's University of Belfast","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ The Queen's University of Belfast"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Inapplicable"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ENX-104","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"LongeVC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ LongeVC","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ LongeVC"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Covar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covar Pharmaceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Covar Pharmaceuticals \/ FSD Pharma"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lucid Psycheceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lucid Psycheceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lucid Psycheceuticals \/ FSD Pharma"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lucid Psycheceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lucid Psycheceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lucid Psycheceuticals \/ FSD Pharma"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Fluorodeschloroketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Wonner Biotech","sponsor":"Shineco","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"SNG","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Beijing Wonner Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Wonner Biotech \/ Shineco","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Wonner Biotech \/ Shineco"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"CKDB-501","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CKD Bio Corporation \/ Healis Therapeutics"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaport Therapeutics \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Seaport Therapeutics \/ General Atlantic"},{"orgOrder":0,"company":"Empyrean Neuroscience","sponsor":"Veteran biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Psilocybin Derivative","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Empyrean Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Empyrean Neuroscience \/ Veteran biotech","highestDevelopmentStatusID":"5","companyTruncated":"Empyrean Neuroscience \/ Veteran biotech"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Estianeptine","moa":"PPA-beta\/delta\/gamma receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trazodone Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropanicant","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ketamine Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Adelia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adelia Therapeutics \/ Cybin","highestDevelopmentStatusID":"3","companyTruncated":"Adelia Therapeutics \/ Cybin"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ ATAI Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"IntelGenx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pasithea Therapeutics \/ EF Hutton","highestDevelopmentStatusID":"1","companyTruncated":"Pasithea Therapeutics \/ EF Hutton"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2020","type":"Series C Financing","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"IntroSpect Digital Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"IntroSpect Digital Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IntroSpect Digital Therapeutics \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"IntroSpect Digital Therapeutics \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Ksana Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Ksana Health","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Ksana Health"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Series B Financing","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ RA Capital Management"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"Ketabon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ketabon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ketabon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ketabon \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"The Centre for Mental Health Research and Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ The Centre for Mental Health Research and Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ The Centre for Mental Health Research and Innovation"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Greenbrook TMS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Greenbrook TMS","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Greenbrook TMS"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hercules Capital"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Journey Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Journey Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Journey Clinical"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Mindful Health Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Mindful Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Mindful Health Solutions"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ TCGX"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Neurocentrx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Neurocentrx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Lophora","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"LPH-5","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lophora","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Lophora \/ Beckley Psytech","highestDevelopmentStatusID":"4","companyTruncated":"Lophora \/ Beckley Psytech"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Inapplicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Inapplicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Inapplicable"},{"orgOrder":0,"company":"Lusaris Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Series A Financing","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lusaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Lusaris Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Lusaris Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Liafensine","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Curia","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Curia"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Liafensine","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Liafensine","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Triptax","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Cellectricon","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cellectricon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectricon \/ Delix Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectricon \/ Delix Therapeutics"},{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Develco Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Develco Pharma \/ HMNC Brain Health","highestDevelopmentStatusID":"8","companyTruncated":"Develco Pharma \/ HMNC Brain Health"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV Channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Enalare Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cessation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cessation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cessation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IRISYS, LLC \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"IRISYS, LLC \/ National Institutes of Health"},{"orgOrder":0,"company":"Indivior","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indivior \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clear Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Clear Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clear Scientific \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clear Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"EP1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"EP1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IPED2015","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Initiator Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Initiator Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dicot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LIB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dicot","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dicot \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dicot \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Cure Pharmaceutical \/ Axiom Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Axiom Capital Management"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Milagro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Cure Pharmaceutical \/ Milagro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Milagro Pharmaceuticals"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Digital Offering, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Digital Offering, LLC","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Digital Offering, LLC"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ IntelGenx"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Seattle Gummy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Inapplicable"},{"orgOrder":0,"company":"MKS Enterprise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Caviar","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"MKS Enterprise","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Sachet","sponsorNew":"MKS Enterprise \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MKS Enterprise \/ Inapplicable"},{"orgOrder":0,"company":"Rubio Laboratories","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Rubio Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Rubio Laboratories \/ Aspargo Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Rubio Laboratories \/ Aspargo Laboratories"},{"orgOrder":0,"company":"Vanquish Group","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Vanquish Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Vanquish Group \/ Aspargo Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Vanquish Group \/ Aspargo Laboratories"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Farmalider SA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Farmalider SA","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Farmalider SA"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Taiba Healthcare"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qilu Pharmaceutical \/ ECI Pharmaceuticals LLC","highestDevelopmentStatusID":"15","companyTruncated":"Qilu Pharmaceutical \/ ECI Pharmaceuticals LLC"},{"orgOrder":0,"company":"CTCBIO INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CTCBIO INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CTCBIO INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTCBIO INC \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emifarma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Emifarma \/ Mangoceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Emifarma \/ Mangoceuticals"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CF602","moa":"Adenosine A3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clomiphene Citrate","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Maryland","sponsor":"Mydecine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of Maryland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland \/ Mydecine","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland \/ Mydecine"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etifoxine Deuterated","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Newleos Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"NTX-1955","moa":"GABAA-gamma-1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Newleos Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.089999999999999997,"dosageForm":"Oral Capsule","sponsorNew":"Newleos Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Newleos Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAA1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"9","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"Invea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Invea Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Invea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"UC San Diego School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ UC San Diego School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ UC San Diego School of Medicine"},{"orgOrder":0,"company":"Creative Bio-Peptides","sponsor":"The Center for Substance Abuse Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"RAP-103","moa":"CXCR-4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Creative Bio-Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creative Bio-Peptides \/ The Center for Substance Abuse Research","highestDevelopmentStatusID":"4","companyTruncated":"Creative Bio-Peptides \/ The Center for Substance Abuse Research"},{"orgOrder":0,"company":"Indivior","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indivior \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Indivior \/ Sanofi"},{"orgOrder":0,"company":"Love Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Love Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Love Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Love Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Indivior \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Aelis Farma"},{"orgOrder":0,"company":"MicroDoz Therapy Inc.","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MicroDoz Therapy Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"MicroDoz Therapy Inc. \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"MicroDoz Therapy Inc. \/ Love Pharma"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GREECE","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmathen SA \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Neuraxpharm"},{"orgOrder":0,"company":"Blumentech S.L.","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Blumentech S.L.","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blumentech S.L. \/ Terran Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Blumentech S.L. \/ Terran Biosciences"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dalriada Drug Discovery \/ ATAI Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Dalriada Drug Discovery \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Clearmind Medicine \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"1","companyTruncated":"Clearmind Medicine \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Research Development Company \/ Clearmind Medicine"},{"orgOrder":0,"company":"MindShift Compounds","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MindShift Compounds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"MindShift Compounds \/ Mind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"MindShift Compounds \/ Mind Medicine"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Vici Health Sciences","sponsor":"Psycheceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vici Health Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vici Health Sciences \/ Psycheceutical","highestDevelopmentStatusID":"4","companyTruncated":"Vici Health Sciences \/ Psycheceutical"},{"orgOrder":0,"company":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics \/ ATAI Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics \/ ATAI Life Sciences"},{"orgOrder":0,"company":"DoubleRainbow Biosciences","sponsor":"Kelai Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"DoubleRainbow Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"DoubleRainbow Biosciences \/ Kelai Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"DoubleRainbow Biosciences \/ Kelai Pharmaceuticals"},{"orgOrder":0,"company":"PsychoGenics","sponsor":"SBIR Grant","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"PsychoGenics \/ SBIR Grant","highestDevelopmentStatusID":"2","companyTruncated":"PsychoGenics \/ SBIR Grant"},{"orgOrder":0,"company":"Psylo","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Psylo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Psylo \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Psylo \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gilgamesh Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gilgamesh Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Queensland","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Queensland \/ ATAI Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"University of Queensland \/ ATAI Life Sciences"},{"orgOrder":0,"company":"University of Alabama","sponsor":"Diamond Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"University of Alabama","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Alabama \/ Diamond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"University of Alabama \/ Diamond Therapeutics"},{"orgOrder":0,"company":"Mycrodose Therapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mycrodose Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mycrodose Therapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Mycrodose Therapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Health \/ Inapplicable"},{"orgOrder":0,"company":"Octarine Bio","sponsor":"Clerkenwell Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Octarine Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Octarine Bio \/ Clerkenwell Health","highestDevelopmentStatusID":"4","companyTruncated":"Octarine Bio \/ Clerkenwell Health"},{"orgOrder":0,"company":"Liechti Lab","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Liechti Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Liechti Lab \/ Mind Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Liechti Lab \/ Mind Medicine"},{"orgOrder":0,"company":"Psylo","sponsor":"University of Sydney","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psylo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Psylo \/ University of Sydney","highestDevelopmentStatusID":"1","companyTruncated":"Psylo \/ University of Sydney"},{"orgOrder":0,"company":"Miami University Broaden","sponsor":"PsyBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Miami University Broaden","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Miami University Broaden \/ PsyBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Miami University Broaden \/ PsyBio Therapeutics"},{"orgOrder":0,"company":"CannaGlobal Wellness","sponsor":"Sansero Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CannaGlobal Wellness","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"CannaGlobal Wellness \/ Sansero Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CannaGlobal Wellness \/ Sansero Life Sciences"},{"orgOrder":0,"company":"Allied Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allied Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Corp \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University Of Health Sciences Antigua","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ University Of Health Sciences Antigua","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ University Of Health Sciences Antigua"},{"orgOrder":0,"company":"Awakened Biosciences","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Awakened Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Awakened Biosciences \/ Core One Labs","highestDevelopmentStatusID":"1","companyTruncated":"Awakened Biosciences \/ Core One Labs"},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"LTS - Lohmann Therapie Systeme \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohmann Therapie Systeme \/ Revive Therapeutics"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"CB Therapeutics \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CB Therapeutics \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"LTS LOHMANN Therapie-Systeme AG","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG","highestDevelopmentStatusID":"5","companyTruncated":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG"},{"orgOrder":0,"company":"Revitalist Lifestyle and Wellness","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revitalist Lifestyle and Wellness","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"Revitalist Lifestyle and Wellness \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revitalist Lifestyle and Wellness \/ PharmaTher"},{"orgOrder":0,"company":"Alexander Shulgin Research Institute","sponsor":"Negev Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Alexander Shulgin Research Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexander Shulgin Research Institute \/ Negev Labs","highestDevelopmentStatusID":"2","companyTruncated":"Alexander Shulgin Research Institute \/ Negev Labs"},{"orgOrder":0,"company":"Field Trip Psychedelics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FT-104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Psychedelics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Field Trip Psychedelics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip Psychedelics \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMND07","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Adelia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tryptamine Derivative","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Adelia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Adelia Therapeutics"},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Psyence","sponsor":"Brandon Kerzner","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Brandon Kerzner","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ Brandon Kerzner"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Pure Extracts Technologies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Pure Extracts Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ Pure Extracts Technologies"},{"orgOrder":0,"company":"Negev Labs","sponsor":"Hadassah Brain Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Negev Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Negev Labs \/ Hadassah Brain Labs","highestDevelopmentStatusID":"2","companyTruncated":"Negev Labs \/ Hadassah Brain Labs"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DSP-2342","moa":"5-HT2A\/5-HT7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supriya Lifescience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supriya Lifescience \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DLX-1","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methamphetamine Hydrochloride","moa":"||5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PH15","moa":"Chemocell receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"SABI Mind","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ SABI Mind","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Health \/ SABI Mind"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALTO-102","moa":"||cyclic-AMP pathway","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"||5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"MiHKAL GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ MiHKAL GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Compass Pathways \/ MiHKAL GmbH"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Methamphetamine Hydrochloride","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University Hospital Basel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Basel \/ Mind Medicine"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"University of Wisconsin","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Wisconsin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Wisconsin \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Wisconsin \/ Revive Therapeutics"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessara Therapeutics","sponsor":"CRC-P","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Tessara Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessara Therapeutics \/ CRC-P","highestDevelopmentStatusID":"2","companyTruncated":"Tessara Therapeutics \/ CRC-P"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Centre for Addiction and Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Centre for Addiction and Mental Health","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avicanna \/ Ei.Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Ei.Ventures"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Exhale Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exhale Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Sairiyo Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Cowen"},{"orgOrder":0,"company":"Katana Pharmaceuticals","sponsor":"March Of Dimes","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Katana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Katana Pharmaceuticals \/ March Of Dimes","highestDevelopmentStatusID":"1","companyTruncated":"Katana Pharmaceuticals \/ March Of Dimes"},{"orgOrder":0,"company":"Curia","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curia \/ Tryp Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Curia \/ Tryp Therapeutics"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"5-HT transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceruvia Lifesciences \/ Yale University","highestDevelopmentStatusID":"5","companyTruncated":"Ceruvia Lifesciences \/ Yale University"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Titan Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"ZMI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"DMK Pharmaceuticals \/ ZMI Pharma","highestDevelopmentStatusID":"15","companyTruncated":"DMK Pharmaceuticals \/ ZMI Pharma"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharmaceuticals L.P \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharmaceuticals L.P \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"The University of New Mexico","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"The University of New Mexico","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"The University of New Mexico \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"The University of New Mexico \/ Purdue Pharma"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Opiant Pharmaceuticals","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Opiant Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Opiant Pharmaceuticals \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Opiant Pharmaceuticals \/ Indivior"},{"orgOrder":0,"company":"Opiant Pharmaceuticals","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Opiant Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Opiant Pharmaceuticals \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Opiant Pharmaceuticals \/ Indivior"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aptar Pharma \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Pharma \/ Indivior"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pocket Naloxone","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"Pocket Naloxone \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pocket Naloxone \/ Inapplicable"},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pocket Naloxone","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"Pocket Naloxone \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pocket Naloxone \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nafamstat Mesylate","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Scienture","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Summit Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Summit Biosciences \/ Scienture","highestDevelopmentStatusID":"15","companyTruncated":"Summit Biosciences \/ Scienture"},{"orgOrder":0,"company":"Proniras","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tezampanel","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Proniras","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proniras \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"1","companyTruncated":"Proniras \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Molteni Farmaceutici"},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Inventage Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inventage Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inventage Lab \/ Inapplicable"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aptar Pharma \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Pharma \/ Indivior"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KUR-101","moa":"MOR","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"DemeRx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ ATAI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"DemeRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Langone Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"NYU Langone Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"18-Methoxycoronaridine","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"8-Methoxycoronaridine HCl","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Kures","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"KUR-101","moa":"MOR","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Kures","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kures \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kures \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Mebias Discovery","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"MEB-1170","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mebias Discovery","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mebias Discovery \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Mebias Discovery \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"NYX-783","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Aptinyx \/ National Institutes of Health"},{"orgOrder":0,"company":"Brains Bioceutical","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Brains Bioceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Brains Bioceutical \/ Icahn School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Brains Bioceutical \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute of Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institutes of Health"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institutes of Health"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Funding","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"Societal CDMO \/ BioCorRx","highestDevelopmentStatusID":"6","companyTruncated":"Societal CDMO \/ BioCorRx"},{"orgOrder":0,"company":"Berkshire Biomedical","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Methadone","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Berkshire Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Berkshire Biomedical \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Berkshire Biomedical \/ National Institute of Drug Abuse"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Grossman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ NYU Grossman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Grossman School of Medicine"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Canntab Therapeutics","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Canntab Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Canntab Therapeutics \/ MediPharm Labs","highestDevelopmentStatusID":"15","companyTruncated":"Canntab Therapeutics \/ MediPharm Labs"},{"orgOrder":0,"company":"Delpor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delpor \/ Inapplicable"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"IRISYS, LLC \/ BioCorRx","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LLC \/ BioCorRx"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cessation Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Cessation Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Alar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"15","companyTruncated":"Titan Pharmaceuticals Inc \/ Indegene Inc"},{"orgOrder":0,"company":"Difgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Difgen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Difgen \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"MMCAP Infuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Buprenorphine","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Purdue Pharma \/ MMCAP Infuse","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ MMCAP Infuse"},{"orgOrder":0,"company":"Difgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Film","sponsorNew":"Difgen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Difgen \/ Inapplicable"},{"orgOrder":0,"company":"Naltrexone Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Naltrexone","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Naltrexone Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Naltrexone Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Naltrexone Therapeutics \/ Love Pharma"},{"orgOrder":0,"company":"Chemify","sponsor":"Prepaire Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Chemify","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemify \/ Prepaire Labs","highestDevelopmentStatusID":"3","companyTruncated":"Chemify \/ Prepaire Labs"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"University of Montana","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Opioid Vaccines","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"University of Montana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Montana \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"University of Montana \/ National Institutes of Health"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Tris Pharma Inc \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zolunicant HCl","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Gilgamesh Pharmaceuticals \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SBS-226","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sparian Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sparian Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Sparian Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Copernicus Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Copernicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Copernicus Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Copernicus Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"EpiVario","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"EpiVario","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVario \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"EpiVario \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Proniras","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Tezampanel","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Proniras","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proniras \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"7","companyTruncated":"Proniras \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"Nobilis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xenon","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Nobilis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nobilis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nobilis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Washington","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Washington"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ NYU Langone Health","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Langone Health"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"University of Sydney","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ University of Sydney"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"CSIRO","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ CSIRO","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ CSIRO"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Granite Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Granite Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Granite Point Capital"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EmpowerPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Inapplicable"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EmpowerPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Bionomics \/ Aegis Capital"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Regent Pacific","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Regent Pacific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cutaneous Spray","sponsorNew":"Regent Pacific \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Regent Pacific \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Kanna Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KH-001 Besylate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Kanna Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kanna Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kanna Health \/ Inapplicable"},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Lorraine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crocus Sativus","moa":"||GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ University of Lorraine","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ University of Lorraine"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Canaccord Genuity","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluphenazine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluphenazine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Loxapine Succinate","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eisai \/ CNX Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ CNX Therapeutics"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Chlorpromazine Hydrochloride","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Piramal Pharma Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Pharma Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"DAAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"DAAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Terran Biosciences"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HTL\u2019149","moa":"GPR52","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMRA-266","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMRA-266","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"UT Health San Antonio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ UT Health San Antonio","highestDevelopmentStatusID":"7","companyTruncated":"PharmAla Biotech \/ UT Health San Antonio"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"HTL0039732","moa":"EP4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry Of Science and Innovation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Spanish Ministry Of Science and Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Spanish Ministry Of Science and Innovation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Vall d\u2019Hebron Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Vall d\u2019Hebron Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Vall d\u2019Hebron Hospital"},{"orgOrder":0,"company":"Gabather","sponsor":"Centre for Neuropsychiatric Schizophrenia Research","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"GT-002","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research"},{"orgOrder":0,"company":"Gabather","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-002","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gabather \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"CAD-9303","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Cowen"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Segal Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Segal Trials","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Segal Trials"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Karuna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PureTech Health \/ Karuna Therapeutics"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Myung In Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Myung In Pharm"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Columbia University \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Oryzon Genomics"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH-1020","moa":"HGF\/MET receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuterated D-serine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuterated D-serine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"HTL0016878","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CVN766","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ML-007","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MapLight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ML-007","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MapLight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ML-007","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MapLight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Tenzing Acquisition"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Tenzing Acquisition"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Citizens JMP"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Citizens JMP"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Titan Partners Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NS-136","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"NeuShen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuShen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuShen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"PDE10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAA1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"TAA1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAA1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ulotaront","moa":"TAA1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals Pvt Ltd"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Aig Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Aig Investments","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Aig Investments"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sarissa Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series E Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sarissa Capital","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sarissa Capital"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Lyndra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Thermo Fisher Scientific \/ Lyndra Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Lyndra Therapeutics"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Bain Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":3.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":3.2999999999999998,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Mitsubishi Tanabe Pharma \/ Bain Capital","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Bain Capital"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Delpor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Delpor \/ Inapplicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ European Investment Bank","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ European Investment Bank"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Royalty Pharma"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Advanz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-101","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"LTS","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"LTS \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"4","companyTruncated":"LTS \/ Livzon Pharmaceutical Group"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Pritzker Neuropsychiatric Disorders Research Consortium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Recognify Life Sciences","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Recognify Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recognify Life Sciences \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Recognify Life Sciences \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Herophilus","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"C4A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Herophilus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Herophilus \/ Cerevel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Herophilus \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Magdalena Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Magdalena Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Jaguar Health \/ Magdalena Biosciences"},{"orgOrder":0,"company":"Zhongze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZZ6398","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Zhongze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhongze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Saniona \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Luvadaxistat","moa":"DAAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CPL500036","moa":"PDE10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurosterix","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurosterix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurosterix \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Neurosterix \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Lieber Institute for Brain Development","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"COMT","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lieber Institute for Brain Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lieber Institute for Brain Development \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Lieber Institute for Brain Development \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Neumora therapeutics \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trospium Prodrug","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Terran Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"K\u00fcleon Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB-128","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"K\u00fcleon Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K\u00fcleon Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"K\u00fcleon Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"EA Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ EA Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ EA Pharma"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV channel-alpha-subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tocagen","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tocagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tocagen \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"Tocagen \/ Ovoca Bio"},{"orgOrder":0,"company":"Ovoca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ovoca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ovoca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovoca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Emotional Brain BV","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Emotional Brain BV"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"1","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"Ananda Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins Psychedelic Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Johns Hopkins Psychedelic Research Group","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Johns Hopkins Psychedelic Research Group"},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Ayrtons Saunders","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ayrtons Saunders","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ayrtons Saunders \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ayrtons Saunders \/ Inapplicable"},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Fertin Pharma AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Fertin Pharma AS \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Fertin Pharma AS \/ Philip Morris International"},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Fertin Pharma AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Fertin Pharma AS \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Fertin Pharma AS \/ Philip Morris International"},{"orgOrder":0,"company":"Miist Therapeutics","sponsor":"Refactor Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"MST-01","moa":"nACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Miist Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Miist Therapeutics \/ Refactor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Miist Therapeutics \/ Refactor Capital"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"QN-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Blue Ledge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Blue Ledge Capital"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Series A Financing","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Blue Ledge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Blue Ledge Capital"},{"orgOrder":0,"company":"Jeeva Clinical Trials","sponsor":"Redwood Scientific Technologies Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Cytisine","moa":"nACh-alpha-5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Jeeva Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Jeeva Clinical Trials \/ Redwood Scientific Technologies Inc","highestDevelopmentStatusID":"11","companyTruncated":"Jeeva Clinical Trials \/ Redwood Scientific Technologies Inc"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Par Pharmaceutical \/ Endo International","highestDevelopmentStatusID":"15","companyTruncated":"Par Pharmaceutical \/ Endo International"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Propel Bio Partners LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Propel Bio Partners LLC","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Propel Bio Partners LLC"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Haleon","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Haleon \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Haleon \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ French Government","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ French Government"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Artemis Biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Partnership","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Artemis Biotech","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Artemis Biotech"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Bpifrance"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"CEA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Collaboration","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ CEA","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ CEA"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SAGE-319","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SBS-518","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sparian Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sparian Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Sparian Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Centers","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delic Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delic Corp \/ Ketamine Wellness Centers","highestDevelopmentStatusID":"1","companyTruncated":"Delic Corp \/ Ketamine Wellness Centers"},{"orgOrder":0,"company":"Nanovo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nanovo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nanovo \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanovo \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanovo","sponsor":"BGN Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Nanovo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nanovo \/ BGN Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Nanovo \/ BGN Technologies"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MagicMed","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MagicMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"MagicMed \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"MagicMed \/ Enveric Biosciences"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PsyBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PsyBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Optimi Health \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaTher \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Revive Therapeutics"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JZP150","moa":"FAAH2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EmpathBio","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"EmpathBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"EmpathBio \/ ATAI Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"EmpathBio \/ ATAI Life Sciences"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Osanetant","moa":"NK-3 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"University of North Carolina \/ Department of Defense"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Helena","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Series A Financing","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Helena","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Helena"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"University Of Nebraska Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ University Of Nebraska Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ University Of Nebraska Medical Center"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"NRx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"||5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Steven & Alexandra Cohen Foundation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Steven & Alexandra Cohen Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Steven & Alexandra Cohen Foundation"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmAla Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Allied Corp","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Allied Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allied Corp \/ HAVN Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Allied Corp \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Nebraska Medical Center \/ Ananda Scientific","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska Medical Center \/ Ananda Scientific"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Everest Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Halucenex Life Sciences \/ Everest Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ Everest Clinical Research"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Halucenex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ InVivium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ InVivium Capital"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"FAAH","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"EmpathBio","sponsor":"Bionomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BNC210","moa":"||nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"EmpathBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EmpathBio \/ Bionomics","highestDevelopmentStatusID":"4","companyTruncated":"EmpathBio \/ Bionomics"},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Apeiron Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Leerink Partners"},{"orgOrder":0,"company":"Bionomics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bionomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Psycheceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Inapplicable"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Ingenu CRO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Psycheceutical \/ Ingenu CRO","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Ingenu CRO"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Psycheceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methamphetamine Hydrochloride","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Unlimited Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unlimited Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Unlimited Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MagicMed","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"MagicMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MagicMed \/ Enveric Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"MagicMed \/ Enveric Biosciences"},{"orgOrder":0,"company":"Mycotopia Therapies","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mycotopia Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycotopia Therapies \/ Ei.Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mycotopia Therapies \/ Ei.Ventures"},{"orgOrder":0,"company":"Emory University","sponsor":"MAPS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"3,4-Methylenedioxymethamphetamine HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Emory University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emory University \/ MAPS","highestDevelopmentStatusID":"8","companyTruncated":"Emory University \/ MAPS"},{"orgOrder":0,"company":"Mydecine","sponsor":"Combat Stress","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Combat Stress","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Combat Stress"},{"orgOrder":0,"company":"Allied Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALID-10","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allied Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Corp \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"MYCO-003","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Research Development Company \/ Clearmind Medicine"},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Research Development Company \/ Clearmind Medicine"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuraxpharm \/ Panaxia","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxpharm \/ Panaxia"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Synendos Therapeutics \/ Ysios Capital"},{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"UMass Dartmouth","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMass Dartmouth \/ Caamtech","highestDevelopmentStatusID":"2","companyTruncated":"UMass Dartmouth \/ Caamtech"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Resyca BV Partner","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Resyca BV Partner","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Resyca BV Partner"},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"PT00114","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagenic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Protagenic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Open Book Extracts","sponsor":"Biopharmaceutical Research Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Open Book Extracts","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Open Book Extracts \/ Biopharmaceutical Research Company","highestDevelopmentStatusID":"1","companyTruncated":"Open Book Extracts \/ Biopharmaceutical Research Company"},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ US Army","highestDevelopmentStatusID":"1","companyTruncated":"PPD \/ US Army"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Pharmalabs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"University of North Carolina \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of North Carolina \/ US Department of Defense"},{"orgOrder":0,"company":"MD Infusions","sponsor":"Front Door Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MD Infusions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Infusions \/ Front Door Health","highestDevelopmentStatusID":"1","companyTruncated":"MD Infusions \/ Front Door Health"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"DLX-007","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Delix Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Delix Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Optimi Health","sponsor":"M\u0101tai Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ M\u0101tai Medical Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Health \/ M\u0101tai Medical Research Institute"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"INDV-1000","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ Caamtech","highestDevelopmentStatusID":"1","companyTruncated":"National Institute on Drug Abuse \/ Caamtech"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CVL-936","moa":"D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"SpineThera \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"SpineThera \/ Mayo Clinic"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"C4X Discovery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"C4X Discovery \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"C4X Discovery \/ Indivior"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavoglurant","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Filament Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Filament Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Filament Health \/ Inapplicable"},{"orgOrder":0,"company":"APIRx","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"APIRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APIRx \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"APIRx \/ Incannex Healthcare"},{"orgOrder":0,"company":"Innovation1 Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin Prodrug","moa":"nACh-alpha-3-beta-4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Innovation1 Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovation1 Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation1 Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Nephron Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Lind Partners"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Smith & Sauer","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Smith & Sauer","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Smith & Sauer"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Laboratorium Ofichem B.V","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Biomedical \/ Laboratorium Ofichem B.V"},{"orgOrder":0,"company":"22nd Century Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"22nd Century Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"22nd Century Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"22nd Century Group \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"mGlu2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Camino Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Camino Pharma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Camino Pharma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"DehydraTECH-Nicotine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pouch","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nACh-alpha-4-beta-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Diverchim S.A.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Diverchim S.A.","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Diverchim S.A."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Public Offering","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"CV Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CV Science \/ Inapplicable"},{"orgOrder":0,"company":"CV Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"||ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CV Science \/ Inapplicable"},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SXC-2023","moa":"SLC7A11","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promentis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Federal Emergency Management Agency","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lofexidine","moa":"Adrenergic-alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Federal Emergency Management Agency","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Federal Emergency Management Agency \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Federal Emergency Management Agency \/ US WorldMeds"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iloperidone","moa":"D2\/5-HT2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iloperidone","moa":"D2\/5-HT2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ro","sponsor":"Greenstone LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ro \/ Greenstone LLC","highestDevelopmentStatusID":"15","companyTruncated":"Ro \/ Greenstone LLC"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ANS-858","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Buspirone Hydrochloride","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Undisclosed"}]
Find Psychiatry/Psychology Clinical Drug Pipeline Developments & Deals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
